Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Endo Plans Valstar Relaunch In Second Half

This article was originally published in The Pink Sheet Daily

Executive Summary

Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.

You may also be interested in...

Endo Reinforces Commitment To Pain With Novel Phase II Drug License

Endo licenses axomadol for chronic pain and diabetic neuropathic pain from Grunenthal; sNDA for Valstar in bladder cancer also approved.

Endo Branches Out With $370M Indevus Acquisition

Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts